Detalhe da pesquisa
1.
Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease.
Regul Toxicol Pharmacol
; 62(2): 329-35, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22057095
2.
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.
Circulation
; 121(21): 2284-93, 2010 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20479152
3.
The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research.
Am J Hum Genet
; 83(3): 347-58, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18760391
4.
The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome.
BMC Cardiovasc Disord
; 8: 6, 2008 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-18366642
5.
Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.
Regul Toxicol Pharmacol
; 52(2): 85-8, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18585425
6.
Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.
Atherosclerosis
; 204(2): 601-7, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19135199
7.
Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study.
Obesity (Silver Spring)
; 17(4): 737-44, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19165155
8.
Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.
J Acquir Immune Defic Syndr
; 49(5): 492-8, 2008 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18989233
9.
Monitoring liver safety in drug development: the GSK experience.
Regul Toxicol Pharmacol
; 49(2): 90-100, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17655994
10.
Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
J Acquir Immune Defic Syndr
; 42(5): 554-61, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16868497